Blog
RSS FeedPosted by Michael Wonder on 30 Oct 2017
Predictive validation and the re-analysis of cost-effectiveness: do we dare to tread?
30 October 2017 - Predictive validation (also known as fourth-order validation) involves the comparison between model outputs and observed data ...
Posted by Michael Wonder on 28 Oct 2017
In search of a common currency: a comparison of seven EQ-5D-5L value sets
24 October 2017 - The recently published EQ-5D-5L value sets from Canada, England, Japan, Korea, the Netherlands, Spain, and Uruguay are ...
Posted by Michael Wonder on 26 Oct 2017
Exploration and preferential ranking of patient benefits of medical devices: a new and generic instrument for health economic assessments
25 October 2017 - For medical devices, benefits other than direct clinical effects may have a large impact on the patients’ ...
Posted by Michael Wonder on 26 Oct 2017
Taking patient heterogeneity and preferences into account in health technology assessments
25 October 2017 - The INTEGRATE-HTA project provided methodology to evaluate complex technologies. ...
Posted by Michael Wonder on 24 Oct 2017
Can ad hoc analyses of clinical trials help personalise treatment decisions?
23 October 2017 - The value of ad hoc analyses of clinical trials may not be clear. Ad hoc analyses are ...
Posted by Michael Wonder on 23 Oct 2017
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
23 October 2017 - NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar ...
Posted by Michael Wonder on 23 Oct 2017
GSK wins U.S. shingles vaccine approval, UK nod for gene therapy
23 October 2017 - GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three ...
Posted by Michael Wonder on 23 Oct 2017
NICE approves gene therapy for rare ‘bubble baby syndrome’
23 October 2017 - Strimvelis, a treatment for an ultra-rare inherited immune deficiency condition that has been dubbed ‘bubble baby syndrome’ ...
Posted by Michael Wonder on 23 Oct 2017
NHS to fund gene therapy for 'bubble babies'
23 October 2017 - The NHS will fund gene therapy for the first time, with a £500,000 treatment for “bubble ...
Posted by Michael Wonder on 23 Oct 2017
Taxpayer-funded drugs 'too expensive for patients’
22 October 2017 - Taxpayer-funded medical research is producing medicines which are increasingly unaffordable for patients who need them, says ...
Posted by Michael Wonder on 20 Oct 2017
National PreP service would be cost effective, research finds
20 October 2017 - Providing pre-exposure prophylaxis treatment to men who have sex with men at high risk of contracting ...
Posted by Michael Wonder on 20 Oct 2017
NICE no for Opdivo in urothelial carcinoma
20 October 2017 - The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for ...
Posted by Michael Wonder on 18 Oct 2017
Economic evaluation of personalised medicine: a call for real-world data
18 October 2017 - In the last decade, we have witnessed a change in healthcare management, with ‘personalised medicine’ as the ...
Posted by Michael Wonder on 17 Oct 2017
‘No-deal’ Brexit could cost NHS £500m a year
17 October 2017 - A ‘no-deal’ Brexit that ends healthcare arrangements between the UK and the EU could end up ...
Posted by Michael Wonder on 16 Oct 2017
Roche’s skin cancer drug Erivedge pulled from CDF
13 October 2017 - Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute ...